Protecting Clients Coast to Coast

If you purchased or otherwise acquired: (a) Firefly common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about August 7, 2025 (the “IPO” or “Offering”); and/or (b) Firefly securities between August 7, 2025 and September 29, 2025, both dates inclusive (the “Class Period”) and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Firefly Aerospace Inc. (“Firefly” or the “Company”) (NASDAQ: FLY) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Firefly had overstated the demand and growth prospects for its Spacecraft Solutions offerings; (2) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (3) the foregoing, once revealed, would likely have a material negative impact on the Company; and (4) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state Lead Plaintiff Deadline: January 12, 2026 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materials overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants statements about Telix’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Lead Plaintiff Deadline: January 9, 2026 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) and reminds investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose key facts about Inspire V, including the actual market demand for the device and whether the company had taken the steps necessary to successfully launch it. Defendants issued a series of materially false and misleading statements that led investors to believe demand for Inspire V was strong and that Company had taken the necessary steps for a successful launch. Lead Plaintiff Deadline: January 5, 2026 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX) and reminds investors of the January 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly overstated CarMax’s growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, defendants statements about CarMax’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Lead Plaintiff Deadline: January 2, 2026 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.